Heron Therapeutics (NASDAQ:HRTX – Get Free Report) is scheduled to release its earnings data before the market opens on Tuesday, November 12th. Analysts expect Heron Therapeutics to post earnings of ($0.03) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.
Heron Therapeutics Price Performance
Shares of HRTX opened at $1.75 on Friday. The company has a market capitalization of $265.42 million, a PE ratio of -5.47 and a beta of 1.81. Heron Therapeutics has a one year low of $0.50 and a one year high of $3.93. The company’s fifty day moving average price is $1.87 and its 200 day moving average price is $2.55.
Analyst Ratings Changes
Separately, Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Heron Therapeutics in a research report on Wednesday, September 25th.
About Heron Therapeutics
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Stories
- Five stocks we like better than Heron Therapeutics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- What is the S&P/TSX Index?
- MarketBeat Week in Review – 11/4 – 11/8
- Are Penny Stocks a Good Fit for Your Portfolio?
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
